Lasa Supergenerics Q4 FY26 Related Party Transactions

Date: May 29, 2026

8. Other Operational / Legal / Strategic Disclosures

Related Party Transactions Disclosure for Q4 and Year Ended March 31, 2026

Director Remuneration:

• Mr. Omkar Herlekar (Promoter-Managing Director): ₹3.00 crore
• Mr. Umesh Pawar (Whole Time Director): ₹1.49 crore
• Mrs Mitti Jain (Company Secretary): ₹5.59 crore
• Mr. Ravi Shankar Kabra (CFO): ₹0.00 crore (approved but not transacted)
• Ms. Varsha Joshi (CFO): ₹1.20 crore
• Mr. Prathmesh Chalke (Whole Time Director): ₹4.63 crore
• Mr. Ganesh Potdar (Whole Time Director): ₹0.30 crore

Independent Director Sitting Fees:

• Ms. Ekta Gurnasinghani: ₹0.75 crore
• Ms. Ajay Sukhwani: ₹1.00 crore
• Mr. Hardesh Tolani: ₹0.75 crore
• Ms. Manali Bhagtani: ₹0.75 crore
• Mr. Yogesh Hari Ughada: ₹0.10 crore
• Mr. Pravin Gadalya Lachake: ₹0.10 crore
• Mr. Ketan Bhau Songal: ₹0.10 crore
• Ms. Rekha Hemant Wakh: ₹0.10 crore

Other Transactions:

• Dr Omkar Herlekar Foundation (Common Director relationship): Donation of ₹15.50 crore

Audit Committee Approvals:

All transactions were 100% approved by the audit committee except:

• Mr. Ravi Shankar Kabra's remuneration: 30% approved
• Independent director sitting fees: 8% approved each

Total Transaction Value: ₹33.41 crore for the reporting period

No material disclosures under the following sections: KMP/Board/Auditor Changes, Dividend Declaration, Board Meeting Outcomes, Financial Results, Auditor's Report, Disinvestment/Strategic Actions, Media Release/Investor Communication.